Picked as SOVS Paper of the Week, the work tests whether the combination boosts activity against WHO-priority resistant pathogens.
Recap by typeshit. Post by Facebook on Facebook.
A Future Health & Medical Innovation panel weighs how much of the growing interest in peptides and exosomes is backed by evidence.
The aging doctor shares a headline saying new studies point to GLP-1 drugs slowing the biological clock, and notes himself that more research is needed.
An explainer on how GLP-1 drugs act on reward and craving in the brain, and the research testing them against alcohol, nicotine and other substance use.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
The pact adds to a busy run of China deals for Roche and is a bet on medicines that lower visceral fat.
He says the peptide has almost no human data and is only sold online as a research chemical, so both the compound and its sourcing carry unknown risks.
Loading…